46 results
8-K
EX-99.1
RLYB
Rallybio Corp
9 May 24
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
8:11am
collaboration with Johnson & Johnson, marking a significant step forward in our mission to eliminate FNAIT and its devastating consequences. Together … -stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio
8-K
EX-99.1
RLYB
Rallybio Corp
10 Apr 24
Entry into a Material Definitive Agreement
4:10pm
with Johnson & Johnson on our mission to eliminate FNAIT,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio. “Our complementary approaches …
Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients
8-K
EX-99.1
29w qledil9vqkz
12 Mar 24
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
8:11am
8-K
EX-99.1
uw7 t0jeauu
6 Feb 24
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
8:15am
8-K
EX-99.1
9wggoarb
20 Dec 23
Regulation FD Disclosure
8:15am
8-K
EX-99.1
6z6nzkhb 1s
9 Nov 23
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
8:10am
8-K
EX-99.1
6zmc7fb8b4c3jqhdn3s
8 Aug 23
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
8:16am
8-K
EX-99.1
ljjgl2 g0v3
29 Jun 23
Departure of Directors or Certain Officers
7:30am
424B3
x2tt8etsr 9tm
12 May 23
Prospectus supplement
4:50pm
8-K
EX-99.1
12wzf4 xoanf
9 May 23
Rallybio Reports First Quarter 2023 Financial Results
8:11am
424B5
iox8 nok2
14 Nov 22
Prospectus supplement for primary offering
8:02am